Meta AnalysisID 6630
参松养心胶囊联合胺碘酮治疗慢性心力衰竭的疗效：一项系统评价与Meta分析
CRD42021281344
Our study hypothesized that the combined SSYXC and AMI treatments can increase the clinical response rate for CHF patients, and can reduce NT-proBNP, QRS wave duration, QT dispersion, total premature ventricular contract
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6630
- Evidence Id
- 15188
- Core Evidence Id
- 15188
- Source Meta Analysis Id
- 6611
- Herb2 Meta Analysis Id
- HBMA006611
- Crd Id
- CRD42021281344
- Title
- The efficacy of combined Shensongyangxin capsule and Amiodaron on the treatments of chronic heart failure: A systematic review and meta-analysis
- Review Question
- Our study hypothesized that the combined SSYXC and AMI treatments can increase the clinical response rate for CHF patients, and can reduce NT-proBNP, QRS wave duration, QT dispersion, total premature ventricular contractions and adverse side effects.
- Study Type Included
- 2.1. Selection of studies Our study collected all randomized paired experiments in published literature that reported the effects from both the combined SSYXC and AMI treatments and the AMI only treatment on CHF in both Chinese and other languages. 2.2. Inclusion criteria Included patients with a diagnosis of CHF based on Guidelines for diagnosis and treatment of acute and chronic heart failure in European Society of Cardiology” (2016 ESC). Cardiac function categories were classified according to classification standards of New York Heart Association (NYHA). Only the experiments with at least 50 CHF cases for each of the combined treatment and control treatment were selected. 2.3. Exclusion criteria Below were excluded: (1) basic clinic research, theoretical research, cell or animal experiments and reviews; (2) control treatments including the compound effects between AMI and other Chinese medicines; (3) missing data or obviously low-quality data; and (4) repeatedly published or full articles are unavailable for access.
- Condition Being Studied
- it provides a systematic review and meta-analysis on the effects of combined Shensongyangxin capsule and Amiodaron on the treatments of chronic heart failure
- Participant
- Based on the retrieved 13 papers, there were a total number of 2, 369 patient cases (1, 187 in the experiment group and 1, 182 in the control group) in this meta-analysis, with an age range from 23 to 85 years’ old. All the studies were conducted in China and published in Chinese. Paired experimental designs, i.e., experimental versus control groups, were applied. Experimental groups included the combined SSYXC, AMI and other regular treatments, while the control groups were treated with AMI and other regular treatments. All the studies reported the clinical response rate.
- Animal
- Human Disease Modelled
- Intervention
- 2.2. Inclusion criteria This study only included patients with a diagnosis of CHF based on “Guidelines for the diagnosis and treatment of chronic heart failure in Chinese adults” or “Guidelines for diagnosis and treatment of acute and chronic heart failure in European Society of Cardiology” (2016 ESC). Cardiac function categories were classified according to classification standards of New York Heart Association (NYHA). Only the experiments with at least 50 CHF cases for each of the combined (SSYXC+AMI) treatment and control (AMI alone) treatment were selected. 2.3. Exclusion criteria Below literatures were excluded in this study: (1) the literature for basic clinic research, theoretical research, cell or animal experiments and reviews; (2) the literature with control treatments including the compound effects between AMI and other Chinese medicines; (3) the literature showing missing data or obviously low-quality data; and (4) the literature that have been repeatedly published or full articles are unavailable for access.
- Comparator Control
- 2.4. Treatments in experimental and control groups Patients in the experimental groups were all treated with combined SSYXC and AMI, and other regular treatments. Patients in the control group included AMI treatment and other regular treatments. The regular treatments included the uses of angiotensin-converting enzyme inhibitor (ACEI), magnetic resonance angiography (MRA), and β-blockers according to the patient conditions. The experiment group or control group which included other interventions were excluded. There were no limitations on dosage and treatment cycle of combined SSYXC and AMI treatments.
- Main Outcome
- Totally 13 studies including 2, 369 experiments were selected. Compared with the AMI only treatment, the combined treatment showed significant differences in the clinical response rate (RR = 0.34, 95% CI: 0.27-0.43; P<0.00001), N-terminal pronatriuretic peptide (NT-proBNP) (MD=-168.47, 95% CI: -291.66─-45.28; P=0.007), part of electrocardiographic wave (QRS) duration (MD=-0.02, 95% CI: -0.02─0.02; P<0.00001), and adverse effects (RR = 0.46, 95% CI: 0.25─0.86; P =0.01). Measures of effect The clinical response rate (RR), N-terminal pronatriuretic peptide (NT-proBNP) , part of electrocardiographic wave (QRS) duration, and adverse effects.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Drugs, Chinese Herbal; Heart Failure; Humans; shensongyangxin
- Contact
- Qihui Jiao [email protected]
- Organisational Affiliation
- Shenzhen Traditional Chinese Medicine Hospital https://www.szszyy.cn/
- Funding Source
- Guangdong Administration of Traditional Chinese Medicine Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> no. 20181225 and 20161227
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-09-23
- Registration Date
- 2021-10-23
- Anticipated Start Date
- 2021-09-24
- Anticipated Completion Date
- 2021-10-25
- Title Cn
- 参松养心胶囊联合胺碘酮治疗慢性心力衰竭的疗效：一项系统评价与Meta分析
- Title En
- The efficacy of combined Shensongyangxin capsule and Amiodaron on the treatments of chronic heart failure: A systematic review and meta-analysis
- Bilingual Status
- complete